Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a research report report published on Monday morning.

Other equities analysts have also issued research reports about the company. Barclays decreased their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Oppenheimer lowered their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. William Blair restated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Finally, Chardan Capital dropped their price target on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Price Performance

NTLA stock opened at $9.36 on Monday. The stock has a market capitalization of $968.92 million, a P/E ratio of -1.72 and a beta of 1.97. Intellia Therapeutics has a 1-year low of $8.30 and a 1-year high of $32.00. The business has a fifty day moving average price of $10.69 and a 200-day moving average price of $15.32.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Large investors have recently made changes to their positions in the business. Polar Asset Management Partners Inc. raised its stake in Intellia Therapeutics by 1,144.1% during the 4th quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company’s stock valued at $3,293,000 after purchasing an additional 259,700 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the fourth quarter valued at approximately $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Intellia Therapeutics by 5.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company’s stock valued at $5,634,000 after buying an additional 23,173 shares during the last quarter. Voloridge Investment Management LLC boosted its position in shares of Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock worth $17,805,000 after acquiring an additional 1,059,751 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new position in Intellia Therapeutics during the fourth quarter valued at $6,122,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.